Latest Breaking News On - தேசிய விரிவான புற்றுநோய் - Page 15 : comparemela.com

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment News provided by Share this article SHANGHAI and HONG KONG, April 28, 2021 /PRNewswire/ With the official release and implementation of the Overall Plan for the Construction of Hainan Free Trade Port, patient can now access global innovative medicines in mainland China. Recently, the global first-in-class selective inhibitor of nuclear export (SINE) compound, selinexor (XPOVIO®), was prescribed for the first time in mainland China at the Boao Super Hospital in Boao Lecheng Pilot Zone and has been authorized to be expanded beyond the Pilot Zone for the outpatient treatment of relapsed or refractory multiple myeloma (rrMM). Prescribing selinexor for the first time in China is a significant milestone in changing the hematological cancer treatment landscape in the country as it allows Chinese

Hong kongHongxia yaoAsia pacificAntengene corporationHematological lymphoma departmentBoao lecheng international medical tourism pilot zoneAntengene corporation limitedPatient programHainan chengmei medicine co ltdNational comprehensive cancer networkNamed patient programBoao super hospitalDiffuse largeb cell lymphomaInterim provisionsImported drugsUrgent need

TodayIR: Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

(1) DJ EQS-News: Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment EQS-News / 29/04/2021 / 11:36 UTC+8 Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment With the official release and implementation of the Overall Plan for the Construction of Hainan Free Trade Port, patient can now access global innovative medicines in mainland China. Recently, the global first-in-class selective inhibitor of nuclear export (SINE) compound, selinexor (XPOVIO(R)), was prescribed for the first time in mainland China at the Boao Super Hospital in Boao Lecheng Pilot Zone and has been authorized to be expanded beyond the Pilot Zone for the outpatient treatment of relapsed or refractory multiple myeloma (rrMM). Prescribing selinex

Hainan provinceHong kongBoao lechengHongxia yaoAsia pacificNational comprehensive cancer network nccnr guidelinesHematological lymphoma department of hainan cancer hospitalAntengene corporation limitedPeople dailyKaryopharm therapeutics incBoao lecheng international medical tourism pilot zoneFinancial pressPatient programName patient programHainan chengmei medicine co ltdNational comprehensive cancer network

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongBoao lechengHongxia yaoAsia pacificAntengene corporationHematological lymphoma departmentAntengene corporation limitedBoao lecheng international medical tourism pilot zonePatient programHainan chengmei medicine co ltdName patient programNational comprehensive cancer networkOverall planHainan free trade portBoao super hospitalBoao lecheng pilot zone

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Hong kongHongxia yaoAsia pacificAntengene corporationHematological lymphoma departmentBoao lecheng international medical tourism pilot zoneAntengene corporation limitedPatient programHainan chengmei medicine co ltdNational comprehensive cancer networkNamed patient programBoao super hospitalDiffuse largeb cell lymphomaInterim provisionsImported drugsUrgent need

New recipients for the 2021 NCCN Foundation Young Investigator Awards announced

New recipients for the 2021 NCCN Foundation Young Investigator Awards announced The National Comprehensive Cancer Network ® (NCCN ®) and the NCCN Foundation ® today announced six new recipients for the 2021 NCCN Foundation Young Investigator Awards (YIA) Program. The honorees will receive up to $150,000 in funding, over two years, to advance important research on important issues in oncology. These early-career investigators from NCCN Member Institutions represent tomorrow s leaders for advancing cancer care. The NCCN Oncology Research Program (ORP) managed the selection process and will provide guidance and oversight for the projects over the grant duration. NCCN is committed to improving the lives of people with cancer by supporting research that is novel, transparent, and meaningful, said Wui-Jin Koh, MD, Chief Medical Officer, NCCN. The NCCN Foundation Young Investigator Awards Program exemplifies this objective by fostering emerging talent and exploring promising area

Everett modingJin kohSanofi genzymeNeelima navuluriEmily hendersonEsra akbayWilliamc jacksonCaitlin zebleyPatrick delaneyDeborah stephensDuke cancer instituteFoundation young investigator awardsSarcoma evolution during tumor developmentAbbvie companyUniversity of utahFoundation young investigator awards program